---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-021902"
form_type: "8-K"
ticker: "RNGE"
cik: "0001438943"
company_name: "RANGE IMPACT, INC."
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:05:40.719389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vitality Biopharma secures $5M equity line; S-1 effective, DTC eligible

## Summary
- SEC declared Form S-1 effective on Sept 2, 2021, registering shares for resale by Triton Funds under a $5M equity line.
- Proceeds from the equity line will fund pre-clinical studies of lead prodrug VBX-100 and general corporate purposes.
- VBX-100, a glycosylated cannabinoid, received FDA Orphan Drug Designation for pediatric ulcerative colitis.
- Common shares deemed DTC eligible effective July 1, 2021, enabling electronic clearing and settlement.
- Only Triton Funds LP may use the prospectus to resell shares under the registration statement.

## SEC filing metadata
- accession: 0001493152-21-021902
- form_type: 8-K
- ticker: RNGE
- cik: 0001438943
- company_name: RANGE IMPACT, INC.
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438943/000149315221021902/0001493152-21-021902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438943/000149315221021902/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-021902
- JSON: https://secwatch.observer/filing/0001493152-21-021902.json
- Plain text: https://secwatch.observer/filing/0001493152-21-021902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.